A Phase 1B Study of DFV890 in People With Myeloid Diseases


Full Title

A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients with Myeloid Diseases


Researchers want to find the best dose of DFV890 to use in people with myeloid diseases. Myeloid diseases include myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). In people with these diseases, certain blood cells are not made correctly and blood counts are low. One cause may be increased inflammatory (stress) signals within MDS or CMML blood cells.

DFV890 may reduce inflammation within myeloid cells, which may help your body make healthy blood cells. It is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have a myeloid disease such as MDS or CMML.
  • Have not had any cancer treatments within 4 weeks of taking DFV890.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Tamanna Haque’s office at 646-608-4166.




Phase I (phase 1)



ClinicalTrials.gov ID